- Abstract viewed - 1114 times
- PDF downloaded - 251 times
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Affiliations
Hiroki Nishikawa
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Yukio Osaki
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Eriko Iguchi
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Haruhiko Takeda
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Yoshiaki Ohara
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Azusa Sakamoto
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Keiichi Hatamaru
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Shinichiro Henmi
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Sumio Saito
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Akihiro Nasu
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Ryuichi Kita
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
Toru Kimura
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan
How to Cite
Percutaneous Radiofrequency Ablation for hepatocellular Carcinoma: Clinical Outcome and safety in Elderly Patients
- Hiroki Nishikawa ,
- Yukio Osaki ,
- Eriko Iguchi ,
- Haruhiko Takeda ,
- Yoshiaki Ohara ,
- Azusa Sakamoto ,
- Keiichi Hatamaru ,
- Shinichiro Henmi ,
- Sumio Saito ,
- Akihiro Nasu ,
- Ryuichi Kita ,
- Toru Kimura
Vol 21 No 4: December 2012
Section: Original Article
Pages: 397-405
Abstract
Background & Aims. We aimed to compare clinical outcomes and safety of radiofrequency ablation (RFA) in single hepatocellular carcinoma (HCC) patients aged >75 years (elderly group) versus patients aged <75 years (control group).
Patients and methods.There were 130 patients in the elderly group and 238 in the control group. Clinical outcomes including overall survival (OS), recurrence free survival (RFS) and local tumor progression (LTP), and safety were analysed for these two groups after initial RFA.
Results. The mean (± standard deviation [SD]) tumor diameter in the elderly and the control groups was 2.13 ± 0.86 cm and 1.92 ± 0.63 cm, respectively; the mean (± SD) observation period was 2.5 ± 1.8 years and 3.2 ± 2.0 years, respectively. The 1 and 3 year OS rates were 90.0 and 64.1%, respectively, in the elderly group and 97.6 and 83.7%, respectively, in the control group (P=0.001); the corresponding RFS rates were 66.9 and 21.3%, respectively, in the elderly group and 80.5 and 40.0%, respectively, in the control group (P=0.001). The 1 and 3 year LTP rates were 15.0 and 43.0%, respectively, in the elderly group and 8.3 and 26.3%, respectively, in the control group (P=0.002). In terms of duration of hospitalization (P=0.807) and serious adverse events related RFA (P=0.670), there was no significant difference between these two groups.
Conclusion. The clinical outcomes in the elderly group were poorer than those in the control group, although RFA in the elderly patients was a safe procedure.